A Phase 3 interventional study of Maridebart cafraglutide and Placebo in Obesity and Obstructive Sleep Apnea, sponsored by Amgen. Active, not recruiting at 61 sites in 11 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.
Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 15th largest by planned enrollment, is one of 11 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 7 of the 16 other live ones, and was the 10th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–70
Amgen · Sites in United States, Canada
Ages 18+
Amgen · Sites in United States, Puerto Rico
Ages 18–99
Amgen · Sites in United States, Canada, Japan and 2 more countries
Ages 18–99
Amgen · Sites in United States, Australia, Canada and 2 more countries
Ages 18–99
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 11 started in 2025.
This study's planned enrollment of 250 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 275 across the 28 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 28 have an industry lead sponsor. The 1 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
32 studies in Obesity by Amgen: 9 open now, 17 under way, 11 of them phase 3. Of 15 finished, 3 (20%) have results posted.
Among the 32 studies in Obesity by Amgen, this one is the 15th largest by planned enrollment of the 31 interventional ones that give a count, is one of 11 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 7 of the 16 other live ones, and was the 14th registered.
Amgen’s Obesity studies by the year they started, since 2018.
9 of the studies testing maridebart cafraglutide in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07871409Phase 3AmgenHome Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | 2027-06-16 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 28 studies testing maridebart cafraglutide in Obesity, from their registry updates:
Among Amgen’s 32 in Obesity:
This tab as a report to print or save as PDF → With an account.
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive maridebart cafraglutide subcutaneously (SC).
Drug: Maridebart cafraglutide
Participants will receive placebo SC.
Drug: Placebo
Participants will receive maridebart cafraglutide as SC injections.
Also known as: AMG 133
Participants will receive placebo SC.
Change in Apnea-Hypopnea Index (AHI) from baseline at week 52
Time frame: At week 52
Percentage Change in AHI from baseline at week 52
Time frame: At week 52
Participants Achieving ≥ 50% AHI Reduction from baseline at week 52
Time frame: At week 52
Participants Achieving AHI < 5 or AHI 5 to 14 with Epworth Sleepiness Scale (ESS) ≤ 10 from baseline at week 52
Time frame: At week 52
Percentage Change in Body Weight from baseline at week 52
Time frame: At week 52
Change in Sleep Apnea-specific Hypoxic Burden (SASHB) from baseline at week 52
Time frame: At week 52
Percentage change in High Sensitivity C-reactive Protein (hs-CRP) from baseline at week 52
Time frame: At week 52
Change in Systolic Blood Pressure from baseline at week 48
Time frame: At week 48
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Sleep-related Impairment 8a Score from baseline at week 52
Time frame: At week 52
Change in AHI from baseline at week 24
Time frame: At week 24
Percentage change in AHI from baseline at week 24
Time frame: At week 24
Change in SASHB from baseline at week 24
Time frame: At week 24
Change in ESS score from baseline at week 52
Time frame: At week 52
Change in PROMIS Short Form v1.0 Sleep Disturbance 8b score from baseline at week 52
Time frame: At week 52
Change in Short Form-36 Health Survey Version 2 (SF-36v2) Acute domain and summary scores from baseline at week 52
Time frame: At week 52
Change from baseline at week 52 in Patient Global Impression of Severity (PGI-S) Sleep-related impairment, Sleep quality, and Sleepiness.
Time frame: At week 52
Percentage of participants achieving ≥ 10% reduction in body weight from baseline at week 52
Time frame: At week 52
Percentage of participants achieving ≥ 15% reduction in body weight from baseline at week 52
Time frame: At week 52
Percentage of participants achieving ≥ 20% reduction in body weight from baseline at week 52
Time frame: At week 52
Change in waist circumference from baseline at week 52
Time frame: At week 52
Change in waist-to-height ratio from baseline at week 52
Time frame: At week 52
Change in neck circumference from baseline at week 52
Time frame: At week 52
Percentage change in Total Cholesterol, High-density lipoprotein cholesterol (HDL-C), Non-HDL-C, Low-density lipoprotein cholesterol (LDL-C), and Triglycerides from baseline at week 52 in fasting conditions
Time frame: At week 52
Percent change from baseline at week 52 in fasting insulin
Time frame: At week 52
Change from baseline at week 52 in fasting plasma glucose (FPG) (mg/dL, mmol/L)
Time frame: At week 52
Change in hemoglobin A1c (HbA1c) (%, mmol/mol) from baseline at week 52
Time frame: At week 52
Change in Diastolic Blood Pressure (DBP) from baseline at week 48
Time frame: At week 48
Number of participants with Treatment-Emergent Adverse Events and Serious Adverse Events
Time frame: Up to 100 weeks
Plasma concentration of maridebart cafraglutide at week 52
Time frame: At week 52
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 20 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2027 → Aug 2027 and completion Aug 2028 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maridebart cafraglutide